Loading…
Chinese maker of complex generic and peptide active pharmaceutical ingredients, including antiviral and specialty drug APIs.
Chinese maker of complex generic and peptide active pharmaceutical ingredients, including antiviral and specialty drug APIs.
Moat: narrow (process know-how). Specialized synthesis capability for complex generics and peptide APIs.
Headquarters: Suzhou, China · Employees: 1,196
Size BrightGene Bio-Medical Technology (688166.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $2.00B, the 1262nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥30.65 on 6 Nov 2026.
Performance Over six months the shares fell 51.4%, against +1.9% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 13.8% over the last twelve months (peer median +7.8%); the operating margin is 7.1% (peer median 18.9%).
Valuation It trades at 87.6× forward earnings against a peer median of 21.2× (most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 39% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is +29 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.1 points below its cost of capital (9.5% WACC).
Next results Next results expected around 25 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.34B | CN¥1.22B | CN¥1.28B | CN¥1.18B | CN¥1.02B |
| Revenue growth | — | -5% | +9% | +16% | — |
| Gross profit | CN¥823M | CN¥570M | CN¥695M | CN¥621M | CN¥604M |
| EBITDA | n/a | CN¥204M | CN¥311M | CN¥288M | CN¥292M |
| Net income | CN¥102M | CN¥54.5M | CN¥189M | CN¥202M | CN¥240M |
| Free cash flow | CN¥158M | -CN¥133M | -CN¥25.8M | -CN¥210M | -CN¥372M |
| Capital expenditure | CN¥278M | CN¥453M | CN¥257M | CN¥404M | CN¥727M |
| Total debt | CN¥2.55B | CN¥2.41B | CN¥2.29B | CN¥2.25B | CN¥2.05B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| BrightGene Bio-Medical Technology 688166.SS | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% |
| Hybio Pharmaceutical 300199.SZ | $3.08B | +16% | +70% | 31% | 51.4× | 40.1% |
| Bachem BANB.SW | $7.32B | +3% | +5% | 19% | 33.1× | n/a |
| PolyPeptide PPGN.SW | $1.62B | +6% | +22% | 7% | 51.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688166.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.3% | -0.8% | 8th lowest of 21 |
| 6-month return | -51.4% | +1.9% | lowest of 21 |
| Distance from 52-week high | -57.9% | -25.3% | lowest of 21 |
| Revenue growth (TTM) | +13.8% | +7.8% | 8th highest of 21 |
| Operating margin | 7.1% | 18.9% | 6th lowest of 21 |
| Forward P/E | 87.6× | 21.2× | most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 38.5% | 6.0% | most demanding of 18 |
| Growth delivered (Del g) | +9.2% | +8.0% | 8th highest of 18 |
| Hurdle (Req g minus delivered) | +29.3 pp | -3.1 pp | 2nd most demanding of 18 |
| ROIC minus cost of capital | -6.1 pp | +0.4 pp | 4th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BrightGene Bio-Medical Technology 688166.SS | China | $2.00B | -51% | +14% | 7% | 87.6× | 38.5% | +9.2% |
| Anhui Anke Biotechnology (Group) 300009.SZ | China | $2.01B | -9% | -9% | 30% | 19.3× | 9.1% | +9.3% |
| United Laboratories International 3933.HK | Hong Kong | $2.00B | -19% | -13% | 5% | 14.5× | 3.7% | +7.8% |
| Alembic Pharmaceuticals APLLTD.NS | India | $2.01B | +24% | +20% | 12% | 24.4× | 25.0% | +6.5% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| ApicHope Pharmaceutical 300723.SZ | China | $1.99B | -28% | -28% | -50% | 25.7× | 14.0% | -11.0% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Sino Biological 301047.SZ | China | $1.98B | +50% | +20% | 17% | 63.8× | 36.8% | -15.1% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Shilpa Medicare SHILPAMED.NS | India | $1.95B | +113% | +28% | 21% | 62.1× | n/a | n/a |
| Tibet Rhodiola Pharmaceutical 600211.SS | China | $1.95B | 0% | +13% | 27% | 13.0× | -0.5% | +16.7% |
| OneSource Specialty Pharma ONESOURCE.NS | India | $1.94B | -12% | +11% | 6% | 45.0× | n/a | n/a |
| Harmony Biosciences HRMY | United States | $1.93B | +7% | +20% | 22% | 8.6× | -10.9% | +40.3% |
| Alivus Life Sciences ALIVUS.NS | India | $1.92B | +32% | +8% | 31% | 24.4× | 20.4% | +6.2% |
| Caplin Point Laboratories CAPLIPOINT.NS | India | $1.92B | +28% | +15% | 31% | 24.6× | 29.3% | +15.7% |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| Shenyang Xingqi Pharmaceutical 300573.SZ | China | $1.91B | -25% | +17% | 33% | 13.7× | 6.0% | +29.1% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |